Core Insights - The report indicates that the market is expected to experience an early "spring rally" due to easing external pressures and improving internal conditions [2][3] - The focus for December should be on growth sectors, particularly those aligned with the "14th Five-Year Plan" and new productive forces [3] Group 1: Market Environment - In November, market momentum was limited due to seasonal effects and external pressures, including tightening global liquidity and concerns over AI industry bubbles [1] - As of December, the pressure on the A-share market is gradually easing, with an 80% probability of a short-term interest rate cut by the Federal Reserve, creating a warmer overall atmosphere [2] - The sentiment around AI stocks has stabilized, reducing the emotional pressure on related A-share sectors [2] Group 2: Investment Recommendations - The report suggests focusing on two main directions for investment in December: the AI industry chain and sectors related to the "14th Five-Year Plan" [3] - Specific sectors to watch include chip design, semiconductor equipment, and platform companies with full-stack technical capabilities [4] - High-growth areas such as energy storage and innovative pharmaceuticals are highlighted as potential investment opportunities [4] Group 3: Top Stock Picks - The report lists ten recommended stocks, including: - BeiGene (688235.SH) in the pharmaceutical sector, with a projected EPS growth from 3.66 in 2026 to 6.73 in 2027 [5] - Haisco (002653.SZ), also in pharmaceuticals, with a projected EPS of 0.70 in 2026 and 0.81 in 2027 [5] - Longking (600388.SH) in environmental services, with a projected EPS of 1.20 in 2026 and 1.37 in 2027 [5] - Maiwei (300751.SZ) in machinery, with a projected EPS of 3.14 in 2026 and 3.93 in 2027 [5] - Yutong Bus (600066.SH) in the automotive sector, with a projected EPS of 2.67 in 2026 and 3.18 in 2027 [5] - Cambricon (688256.SH) in electronics, with a projected EPS of 11.64 in 2026 and 20.88 in 2027 [5] - CATL (300750.SZ) in new energy, with a projected EPS of 18.90 in 2026 and 23.35 in 2027 [5] - Alibaba (9988.HK) in media and internet, with a projected EPS of 4.33 in 2026 and 6.44 in 2027 [5] - Xianle Health (300791.SZ) in food and beverage, with a projected EPS of 1.37 in 2026 and 1.64 in 2027 [5] - Wanhua Chemical (600309.SH) in energy and chemicals, with a projected EPS of 5.13 in 2026 and 5.79 in 2027 [5] Group 4: Financial Data - The report provides financial forecasts for the top stock picks, indicating expected revenue and net profit growth across various sectors [62][63] - For example, BeiGene is projected to achieve a revenue of 370.27 billion in 2025, increasing to 462.80 billion in 2026 [63] - CATL is expected to see significant growth, with projected revenues of 4226.04 billion in 2025 and 5349.47 billion in 2026 [63]

Report Industry Investment Rating No information provided. Core Viewpoints of the Report - In 2026, the uncertainty in the macro - environment is expected to decline. China's economic growth may be driven by rebalancing, with a slight slowdown to 4.7%. The US economy may be driven by fiscal - stimulated consumption and AI investment, and there may be three 25 - basis - point interest rate cuts by the end of next year [3][10]. - In the Chinese market, valuation growth will shift from being liquidity - driven to profit - driven. Hong Kong stocks are cost - effective. Investment should focus on high - growth stocks and core asset themes such as overseas expansion, AI, and new consumption [3][10]. - In the consumer industry, the competitive environment is expected to improve. The investment strategy is to embrace new trends and new consumption. Traditional consumer industries offer opportunities in individual stock fundamental reversals, while new consumer companies focus on valuation rebounds after improved performance certainty [3][10]. - The pharmaceutical industry is optimistic. The innovative drug and CXO sectors are recommended due to factors like China's innovative drug R & D capabilities, policy support, and expected improvement in overseas biopharmaceutical investment and financing [4][10]. - The AI industry in the technology sector will continue to grow strongly, driving the growth of multiple industries and experiencing explosive demand growth in downstream applications [4][10]. Summary According to Related Catalogs 2026 China Macroeconomic Outlook: The Road to Economic Rebalancing in the First Year of the 15th Five - Year Plan - **Core Situation in 2025**: Thanks to pre - emptive policy efforts and better - than - expected external demand, the annual economic growth target of about 5% can be achieved. However, economic development still faces challenges such as imbalance between supply and demand, the unstable real estate industry, and low inflation [11][16]. - **2026 Outlook**: - **External and Internal Uncertainties**: External trade relations between China and the US may reach a new dynamic balance, and internal risks such as local government debt and real estate have decreased [17]. - **Challenges**: Economic imbalance persists, the real estate industry remains unstable, and low inflation affects investment and consumption confidence [18][19]. - **Policy**: Fiscal policy will maintain a 4.0% budget deficit rate, issue 1.6 trillion yuan in ultra - long - term special treasury bonds, and may increase local government special bonds. It focuses on promoting consumption and stabilizing investment. Monetary policy will remain loose, with possible interest rate cuts of 10 - 20 basis points and reserve requirement ratio cuts of 50 - 100 basis points. Real estate policies will be moderately advanced [21][22]. - **Economic Growth**: Real economic growth is expected to slow to 4.7%. Consumption and investment will contribute 4.3 percentage points, higher than in 2025. The economic growth rate may be low in the first half and high in the second half. Inflation is expected to improve, with the CPI rising to 0.6% and the nominal GDP growth rate rising to 4.5%. The US dollar - RMB exchange rate will remain stable [23][24]. 2026 US Macroeconomic Outlook: The Road to Economic Recovery Led by Policy Stimulus No information provided. 2026 China Market Strategy Outlook: Demand - Driven Growth, Embracing New Core Assets - **Investment Strategy**: China's market liquidity will remain abundant, but valuation growth will be profit - driven. Hong Kong stocks are cost - effective. Investment should focus on high - growth stocks and core asset themes like overseas expansion, AI, and new consumption [10]. Consumer Industry 2026 Outlook: Find Opportunities in the Quiet and the Ordinary - **Industry Environment**: In a weak demand recovery environment, the competitive environment is expected to improve through upstream capacity reduction, downstream inventory clearance, and anti - involution [10]. - **Investment Strategy**: The key is to embrace new trends and new consumption. High - cost - performance domestic substitution, emotional consumption, health - related consumption, new retail formats, and domestic brands going overseas are important investment directions. Traditional consumer industries focus on individual stock fundamental reversals, and new consumer companies focus on valuation rebounds [10]. - **Preferred Stocks**: Pop Mart (9992.HK), Luckin Coffee (LKNCY.US), and Topsports (6110.HK) are preferred in 2026 [10]. Pharmaceutical Industry 2026 Outlook: Reach New Heights - **Optimistic Outlook**: The pharmaceutical sector is optimistic. The innovative drug sector is recommended due to China's leading R & D capabilities, policy support, and more biotech companies entering the profit stage. The CXO sector is also promising as overseas biopharmaceutical investment and financing is expected to improve [4][10]. Technology Industry 2026 Outlook: AI Algorithm Iteration Expands the Computing Power Base, and the Prosperous Ecosystem Reshapes the Growth Boundary - **AI Growth**: The AI industry will continue to grow strongly. Its underlying technology is in a flywheel - iteration stage, driving the growth of multiple industries and experiencing explosive demand growth in downstream applications such as C - end, B - end, and G - end. In the long run, it may bring growth to emerging industries like embodied intelligence [4][10].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The retail pharmacy sector is expected to benefit from the recent surge in flu cases, with a significant increase in demand for antiviral medications and symptomatic treatments [5][15] - The retail pharmacy industry is anticipated to undergo accelerated consolidation, with smaller pharmacies exiting the market, leading to increased customer traffic for leading players [6][34] - The implementation of drug traceability codes is expected to enhance industry compliance and further increase market concentration [6][18] Summary by Sections Industry Overview - The closing index for the industry is 8430.03, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - The A-share pharmaceutical sector rose by 2.67% from November 24 to November 28, 2025, outperforming the CSI 300 index by 1.03 percentage points [19][35] - The Hang Seng Healthcare Index increased by 3.64%, outperforming the Hang Seng Index by 1.1 percentage points [35][36] Industry Insights and Investment Recommendations 1. **Innovative Drugs**: The long-term trend for innovative drugs is positive, with China's capabilities in global competition strengthening [9][21] - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and others [10][22] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3 [10][26] - Recommended stocks include Mindray, Aohua Endoscopy, and others [27][28] 3. **Traditional Chinese Medicine**: The sector is under pressure but is expected to benefit from basic drug policies and innovation [31][32] - Recommended stocks include Zhaoke Ophthalmology, Fangsheng Pharmaceutical, and others [31][32] 4. **Retail Pharmacy**: The retail pharmacy sector is expected to see increased concentration, with leading pharmacies benefiting from enhanced service capabilities and supply chain management [6][34] - Recommended stocks include Yifeng Pharmacy and Dazhong Pharmacy [7][34]

Group 1: Non-ferrous Metals - The non-ferrous metal sector has shown a steady recovery in revenue and profit growth, with midstream smelting and processing profits rebounding [2] - The sector's profitability continues to improve, with a decrease in leverage ratios and cash flow growth maintaining an upward trend [2] - Positive factors for metals such as silver, copper, tin, and rare earths are driving price increases, with continued optimism for metals like gold, silver, copper, aluminum, and lithium [2] Group 2: Communication - The global quantum technology industry is expected to grow at a CAGR of 76.27% from 2024 to 2030, with a projected market size of $908.91 billion by 2035 [3] - The demand for isolators is expected to grow alongside the surge in optical module demand, becoming a significant upstream component [3] - The communication ETF has seen a 3.01% increase, with over 60% growth year-to-date [3] Group 3: Chip Industry - ByteDance's Doubao team has launched a technical preview of the Doubao mobile assistant, which integrates AI capabilities for enhanced user interaction [4] - The semiconductor industry is anticipated to benefit from AI-driven hardware opportunities and domestic substitution processes amid external restrictions [4] - The chip ETF has increased by 1.82%, being the only product in its category to show positive growth year-to-date [4] Group 4: Agriculture, Forestry, Animal Husbandry, and Fishery - The agricultural sector is stabilizing as China continues to promote seed industry revitalization and improve grain yields [6] - Global weather disruptions may lead to a decrease in overall crop yields, potentially improving the agricultural industry's outlook [6] - The grain ETF is gaining attention as it covers the entire grain industry chain [6] Group 5: Hong Kong Innovative Drugs - The innovative drug sector is experiencing a temporary sentiment decline, but the overall trend remains positive with ongoing internationalization [7] - The largest Hong Kong innovative drug ETF has reached a scale of 25.276 billion yuan, indicating significant market interest [7] Group 6: Manufacturing PMI - China's manufacturing PMI for November was reported at 49.2%, showing a slight improvement from October [9] - The production index and new orders index have increased, indicating a recovery in manufacturing activity [9] Group 7: Engineering Machinery - The engineering machinery sector is witnessing a recovery in demand, with sales of excavators and loaders continuing to grow [10] - The industry is expected to benefit from ongoing domestic investment strategies and major project implementations [10] - The largest engineering machinery ETF has seen continuous net inflows over the past three days [10]

Group 1 - The core viewpoint is that global giants are significantly increasing capital expenditure, shifting the market focus towards the commercialization of AI applications in the coming year [1] - AI is expected to continue its rapid penetration, with mature terminal hardware technology, clear implementation paths, and quick value realization [1] - Domestic manufacturing leaders are deeply integrated into the supply chains of top terminal brands, creating competitive barriers in core components and assembly processes due to their vertical integration capabilities and global supply chain layout [1] Group 2 - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), covering core assets in Hong Kong such as Internet, semiconductors, innovative pharmaceuticals, and new energy vehicles [1] - The Hong Kong Stock Connect Technology Index has a higher allocation in new energy vehicles, innovative pharmaceuticals, and semiconductors compared to the Hang Seng Technology Index [1] - From the base date at the end of 2014 to the end of October 2025, the cumulative return of the Hong Kong Stock Connect Technology Index is 256.46%, outperforming the Hang Seng Technology Index by nearly 160% [1]

Group 1: Federal Reserve and Market Expectations - Goldman Sachs indicates that the Federal Reserve is expected to lower interest rates during the December 9-10 meeting, with a nearly certain probability of a 25 basis point cut at around 85%-86% [1] Group 2: Company Developments - Baillie Gifford's subsidiary SystImmune received a $250 million milestone payment from Bristol-Myers Squibb related to the global strategic collaboration agreement, with potential for up to $2.5 billion in near-term or contingent payments and an additional $7.1 billion upon achieving specific development, registration, and sales milestones [1] - Innovent Biologics announced that its self-developed drug, Xinmeiyue® (Pikankizumab injection), has been approved by the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis in adult patients, marking a significant advancement in domestic precision treatment for psoriasis [1] Group 3: Market Performance and Trends - The Hong Kong Stock Connect Innovation Drug ETF (159570) experienced a decline of over 1% for two consecutive days, with a trading volume exceeding 1 billion yuan, and a net inflow of 80 million yuan during the day [3] - As of November 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) exceeded 24 billion yuan, leading its peers in the same category [3] Group 4: Upcoming Events and Industry Catalysts - The results of the drug catalog negotiation conducted by the Medical Insurance Bureau are expected to be released in the first weekend of December, with a focus on the inclusion of domestic biological innovative drugs for skin diseases in the medical insurance [4] - The American Society of Hematology (ASH) conference is set to take place from December 6-9, where multiple differentiated hematology products will have data disclosed, with a focus on companies like BeiGene, Innovent Biologics, and others [4] Group 5: Company Stock Performance - The weighted stocks of the Hong Kong Stock Connect Innovation Drug ETF (159570) showed mixed performance, with major stocks like Rongchang Bio down over 5%, while Innovent Biologics and Hansoh Pharmaceutical saw slight increases [1][2]

Group 1 - The core viewpoint of the article emphasizes the potential for a bull market in A-shares driven by global capital inflows, as highlighted during the 2025 Analyst Conference [1][2] - The first major highlight of the "14th Five-Year Plan" is the acceleration of "technological self-reliance," aiming to create a new Chinese technology industry focused on future manufacturing, information, materials, energy, space, and health [1][17] - The second highlight is the construction of a strong domestic market, with a focus on boosting consumption and sectors such as innovative pharmaceuticals and the silver economy/elderly care industry [2][29] Group 2 - The third highlight involves decisively removing obstacles to the construction of a unified national market, which is crucial for the comprehensive domestic substitution of the entire Western industrial chain, particularly in electronics, computing, and communications [2][42] - The article discusses the importance of enhancing the domestic circulation's internal dynamics and reliability through policies that directly benefit consumers and increase government spending on social welfare [32][33] - It also mentions the need for structural adjustments to increase the proportion of disposable income for residents and optimize fiscal expenditure structures to support consumption [33][34] Group 3 - The article outlines the future industrial space, emphasizing the need for advancements in high-tech industries, including next-generation communication, quantum technology, and biomanufacturing [19][22] - It highlights the importance of increasing R&D investment as a percentage of GDP, aiming for a more significant focus on original innovation and key core technology breakthroughs [25][26] - The article notes that the construction of a unified national market is a systematic project requiring multi-faceted cooperation and policy alignment across various levels [41]

Investment Rating - The industry investment rating is "Outperform the Market" [1][31]. Core Viewpoints - The report highlights the initiation of centralized procurement for electrophysiology and neuro-interventional medical consumables in Beijing, which is expected to promote the entry of domestic high-end products and accelerate domestic substitution [4]. - The procurement covers all public medical institutions in Beijing, with a two-year agreement period, and includes various categories of electrophysiology and neuro-interventional products [4]. - The report suggests focusing on leading companies with comprehensive layouts in the electrophysiology field, such as Huatai Medical and Microelectrophysiology [4]. Summary by Sections Industry Overview - The centralized procurement for electrophysiology and neuro-interventional consumables has officially started, with a deadline for submission set for December 1 [4]. - The procurement is led by six top-tier hospitals in Beijing and aims to enhance the availability of domestic products [4]. Investment Strategy - The report recommends attention to innovative drug companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China Biopharmaceuticals [6]. - It also highlights companies with significant single-product potential and those leading in advanced technology platforms [6]. Market Performance - The pharmaceutical sector saw a 2.67% increase last week, outperforming the CSI 300 index, which rose by 1.64% [9][20]. - In the Hong Kong market, the pharmaceutical sector increased by 3.85%, leading among 11 sectors [30]. Notable Industry News - Abbott announced a $21 billion acquisition of Exact Sciences, enhancing its position in the cancer diagnostics field [13]. - Johnson & Johnson is acquiring Halda Therapeutics for $3.05 billion, focusing on prostate cancer treatments [14]. - A significant ophthalmic drug has been approved for market release, expanding treatment options for age-related macular degeneration [16]. - Novartis received approval for its oral drug Remibrutinib in China, targeting chronic spontaneous urticaria [17].

Core Viewpoint - The pharmaceutical sector has shown a volatile upward trend since early 2025, with a brief correction highlighting its cost-effectiveness, despite current valuations being at historical medians since 2010, indicating room for market capitalization growth [1] Group 1: Innovative Drug Industry Chain - Emphasis on innovation and the importance of high-quality domestic clinical data to catalyze opportunities for profit recovery in the industry [2] - Domestic assets are gaining global recognition, with strong demand for new product iterations and favorable conditions for domestic new drugs to enter international markets [2] - The dual-antibody market (PD-(L)1/VEGF) is experiencing increasing market heat and transaction value, with potential for synergistic effects alongside ADC mechanisms [2] Group 2: New Therapeutic Approaches - High demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to maintain rapid growth, with a recovery in outsourcing demand anticipated during the overseas interest rate decline [3] - The domestic market is poised for a recovery in demand and primary market conditions, with a potential for rapid profit recovery as supply-side capacity reduction slows [3] Group 3: Non-Pharmaceutical Sector - Medical devices are showing signs of a turning point, with growth stabilizing for certain companies and a recovery in bidding processes expected to impact 2026 performance positively [4] - The traditional Chinese medicine sector is likely to see continued adjustments in essential drug catalogs, with opportunities arising from price declines in raw materials [4] - Retail pharmacies are undergoing accelerated consolidation, with leading pharmacies optimizing store structures to alleviate profit pressures, leading to expected profit margin improvements in 2026 [4]

Market Overview - Hong Kong stocks experienced a volatile trend in November, with the index fluctuating between 25,178.63 and 27,188.81 points, failing to break the 27,000-point mark or drop below 25,000 points [1][2] - The market was initially buoyed by the anticipated end of the U.S. government shutdown and easing tensions between China and the U.S., but later faced declines due to concerns over potential interest rate cuts by the Federal Reserve and geopolitical tensions in the Taiwan Strait [1][2] Sector Performance - Bank stocks performed well, with several state-owned banks reaching historical highs, while innovative drug companies like BeiGene (06160) also saw significant gains [2] - Solid-state battery stocks showed strong performance, driven by trends in energy storage and price increases, with notable gains from companies like Longpan Technology (603906) and Weichai Power (000338) [2] Economic Indicators and Expectations - The Federal Reserve's December meeting is a key focus, with market expectations for a rate cut rising significantly, from about 30% to 80% following dovish comments from Fed officials [3] - Upcoming economic work meetings in December are expected to provide guidance on fiscal and monetary policies, with potential increases in deficit rates and special bond quotas [4] Currency and International Factors - The Chinese yuan continues to appreciate against the U.S. dollar, indicating strong domestic factors driving this trend, alongside positive sentiment from foreign investors towards Chinese assets [5] - The market is closely monitoring Japan's potential interest rate hike, which could lead to capital inflows into undervalued Hong Kong stocks [5] Investment Strategies - The investment strategy for December emphasizes following market expectations, particularly regarding policy changes and major events [7][8] - Key sectors to watch include technology, consumer goods, and innovative pharmaceuticals, with a focus on companies that are well-positioned to benefit from upcoming trends and events [8] Company Highlights - **Rongchang Bio (09995)**: Reported a revenue of 1.72 billion yuan for the first three quarters of 2025, a year-on-year increase of 42.3%, with a gross margin of 84.27% [11] - **Leap Motor (09863)**: Achieved a revenue of 19.45 billion yuan in Q3 2025, a year-on-year increase of 97.3%, with a net profit of 150 million yuan [14] - **TCL Electronics (01070)**: Reported a 8.7% increase in TV sales revenue for the first three quarters of 2025, with a significant rise in MiniLED TV sales [16][17] - **MGM China (02282)**: Announced a net income of 8.51 billion HKD in Q3 2025, a 17% year-on-year increase, driven by strong high-end demand [28][29] - **China Gold International (02099)**: Achieved a revenue of 925 million USD in the first three quarters of 2025, nearly doubling year-on-year, with a significant increase in gold and copper production [30][31]